Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

Why Did Suboxone ANDA Applicant Forfeit 180-Day Exclusivity? US FDA's Answer Sets New Policy

Jul 25 2018

• By Brenda Sandburg

FDABldg1ExteriorWithCircle_1200x675

Related Content

Indivior Withdraws 2018 Guidance Due To Competitive Pressures On Suboxone, Sublocade

Jul 11 2018

Dr. Reddy's Launches First Generic Suboxone Film; Indivior May Seek Injunction

Jun 17 2018

Indivior To Appeal US Suboxone Setback, Flags Follow-On Drug RBP-6000

Sep 02 2017

Related Companies

Indivior plc

Dr. Reddy's Laboratories Ltd.

Viatris Inc.

Additional Topics

United States Regulation FDA Generic Drugs Legal Issues BioPharmaceutical

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window